Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Prior authorization leeway will be trimmed while health plans get more money under new federal rules for Medicare Advantage ...

Stocks rose Monday after wavering earlier in the session as the Trump administration exempted smartphones and other ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...